The U.S. Food and Drug Administration has selected Eli Lilly and Regeneron among seven companies for a pilot program to accelerate reviews of new domestic pharmaceutical manufacturing facilities, according to CNBC.
Program Details
The program, called the PreCheck pilot program, will allow regulators to start reviewing new manufacturing facilities while they are being built to catch and correct any issues, which the FDA estimates could save companies up to 14 months.
The other companies participating in the program are Amneal, Cellares, Fujifilm Biotechnologies, Kriya Therapeutics, and Kyowa Kirin.
Original reporting: Appleton, WI News Feed (HLL/CB) — read the source article.
